Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Current Taxes Dividends payables Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Income Statement

Others

Ratios

Zhengye Biotechnology Holding (ZYBT) Other Non-Current Liabilities (2024)

Zhengye Biotechnology Holding has reported Other Non-Current Liabilities over the past 1 years, most recently at $20325.5 for Q4 2024.

Quarterly Other Non-Current Liabilities changed N/A to $20325.5 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $20325.5 through Dec 2024, changed N/A year-over-year, with the annual reading at $20000.0 for FY2024, N/A changed from the prior year.
Other Non-Current Liabilities was $20325.5 for Q4 2024 at Zhengye Biotechnology Holding.
Over five years, Other Non-Current Liabilities peaked at $20325.5 in Q4 2024 and troughed at $20325.5 in Q4 2024.